A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
Status:
Recruiting
Trial end date:
2023-06-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and tolerability of JNJ 66525433 compared
with placebo after administration of: 1) single ascending oral doses of JNJ 66525433
administered to healthy participants (Part 1), 2) multiple, ascending oral doses of JNJ
66525433, administered to healthy participants once daily over 14 consecutive days (Part 2),
and 3) multiple oral doses of JNJ 66525433, administered once daily over 14 consecutive and
once daily over 42 consecutive days in participants with ulcerative colitis (UC) (Part 3).